Cholinergic Mechanisms in Alzheimer’s Disease

The cholinergic system, centred on neurons synthesising and releasing acetylcholine, plays a pivotal role in attention, learning and memory. In Alzheimer’s disease, early degeneration of basal forebrain cholinergic neurons disrupts cortical and hippocampal circuits, contributing to cognitive decline. Loss of cholinergic tone arises from reduced synthesis of acetylcholine, atrophy of the nucleus basalis of Meynert and impaired synaptic transmission. Interactions with amyloid-β and tau pathologies exacerbate cholinergic dysfunction, while chronic neuroinflammation accelerates neuronal vulnerability. Symptomatic treatments with acetylcholinesterase inhibitors restore synaptic acetylcholine levels transiently, but do not halt neurodegeneration. Emerging strategies aim to rescue cholinergic circuits via neuromodulation, targeted delivery of neurotrophic factors and selective receptor agonists. Understanding the spatial and temporal progression of cholinergic decline has global significance for developing disease-modifying therapies and improving quality of life for the ageing population.

Research from Nature Portfolio

Longitudinal imaging studies have demonstrated that volume loss in basal forebrain nuclei precedes degeneration of entorhinal cortex and predicts subsequent memory impairment. These findings challenge the view of a purely cortical origin of Alzheimer’s pathology, suggesting that early cholinergic decline may prime downstream neurodegenerative cascades. In a randomised trial of prodromal Alzheimer’s patients, treatment with a cholinesterase inhibitor over twelve months significantly reduced the rate of atrophy within basal forebrain cholinergic nuclei, particularly in the nucleus basalis of Meynert and medial septum. Preservation of these nuclei correlated with slower progression of hippocampal and cortical thinning, indicating that early symptomatic intervention can confer neuroprotective benefits beyond transient cognitive improvement.

Cholinergic Mechanisms in Alzheimer’s Disease publication trend

The graph below shows the total number of articles in cholinergic mechanisms in alzheimer’s disease across all publications each year (not limited to Nature Index journals).

Technical terms

Basal forebrain cholinergic system: A group of neurons in the basal forebrain that release acetylcholine to modulate cortical and hippocampal activity.

Medial septum–hippocampal circuit: A neural pathway connecting the medial septal nuclei to the hippocampus, important for rhythm generation and memory consolidation.

Theta rhythm: Oscillatory activity in the 4–8 Hz frequency band that supports hippocampal-dependent learning and memory processes.

Acetylcholinesterase inhibitors: Drugs that block the enzyme breaking down acetylcholine, thereby enhancing cholinergic neurotransmission.

Neuroinflammation: Chronic activation of glial cells, notably microglia and astrocytes, that can exacerbate neuronal damage.

Neurotrophic factors: Proteins such as nerve growth factor that support neuron survival, growth and phenotypic maintenance.

References

1. Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation. Molecular Neurodegeneration (2023).
2. Chronic neuroinflammation during aging leads to cholinergic neurodegeneration in the mouse medial septum. Journal of Neuroinflammation (2023).
3. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology. Nature Communications (2016).
4. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Frontiers in Neuroscience (2019).
5. Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience (2019).
6. Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease. Scientific Reports (2017).
7. Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?. International Journal of Molecular Sciences (2020).